Merck (MRK) Trading Higher After Strong Q3 Earnings

Dow component Merck & Co., Inc. (MRK) is trading higher by about 1% in Tuesday's pre-market after booking a third quarter 2020 profit of $1.74 per share, $0.31 better than consensus estimates. Revenue rose a modest 1.2% year over year to $12.55 billion, also beating expectations. The pharmaceutical giant topped off the bullish report by raising 2020 guidance more than 10%, but the weak post-news reaction highlights continued investor apathy.

Key Takeaways

  • Merck beat third quarter top- and bottom-line estimates and raised full-year guidance.
  • The modest post-news reaction highlights persistent investor apathy.
  • The 3.07% dividend is more attractive than the mixed price pattern.

Merck has a deep pipeline of cancer, pain management, and HIV treatments but joined the COVID-19 hunt later than its rivals and just started early trials. Merck shares rallied with pandemic-focused stocks mid-year, when the broad sector attracted a strong bid, but have now settled into a bearish pattern that has sliced through support at the 50- and 200-day exponential moving averages (EMAs). The $81.50 level marks the dividing line between bull and bear power in this price structure, or about two points above this morning's opening print.

Wall Street rates Merck as a "Moderate Buy" based upon eight "Buy" and three "Hold" recommendations. No analysts are recommending that shareholders close positions and move to the sidelines. Price targets currently range from a low of $84 to a Street-high $105, while the stock is set to open the session about $4 below the low target. This divergence highlights the current attraction to tech and other growth sectors, rather than old-school pharma plays. Even so, the 3.09% forward dividend yield is keeping current shareholders in place.

A public company's guidance is its report to shareholders on the earnings it expects to achieve in the quarter or fiscal year ahead. Alternatively referred to as earnings guidance or a forward-looking statement, the report typically includes revenue estimates, projected earnings, and capital spending estimates.

Merck Monthly Chart (2000 – 2020)

Chart showing the share price performance of Merck & Co., Inc. (MRK) 

A multi-year uptrend topped out at $96.69 in November 2000, marking a high that wasn't challenged for the next 20 years, ahead of an persistent downtrend that carved three broad selling waves into March 2009's 13-year low in the mid-$20s. A slow-motion recovery completed a round trip into the 2007 swing high in the low $60s in 2014, yielding a quick rally, followed by a failed breakout that reinforced resistance.

A second breakout after the 2016 presidential election suffered the same fate, topping out in the mid-$60s in the first quarter of 2017. The stock posted a two-year low at $52.83 in April 2018, marking the best buying opportunity of the decade, ahead of a steady advance that completed the three-year breakout attempt in the third quarter. The uptrend posted solid returns into December 2019, when it reversed within four points of the 2000 high.

Merck Short-Term Outlook

The stock sold off to a two-year low during the first quarter and bounced in two rally waves, reversing at the .786 Fibonacci selloff retracement level in September. It has now crossed into a monthly stochastic sell cycle, predicting mixed action into the first quarter of 2021. More importantly, accumulation readings have plummeted since posting an all-time high in December 2019, warning that institutions have pulled up stake in favor of other opportunities.

In the shorter term, Merck stock is extremely oversold on a weekly basis, raising the odds for an intermediate bounce that will face a buzz-saw of resistance in the mid- to upper $80s. A buying spike above the September high at $87.80 is needed to improve the longer-term outlook and set up supportive conditions for a test at the 2019 high. Unfortunately, that doesn't seem to be in the cards in the fourth quarter.

Oversold refers to a condition where an asset has traded lower in price and has the potential for a price bounce. An oversold condition can last for a long time, and therefore being oversold doesn't mean a price rally will come soon, or at all. Many technical indicators identify oversold and overbought levels.

The Bottom Line

Merck stock is trading higher after a strong third quarter earnings report, but persistent investor apathy is likely to continue. 

Disclosure: The author held no positions in the aforementioned securities at the time of publication.

Take the Next Step to Invest
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.